Search
Inhibikase Therapeutics Inc
IKTAdd to Watchlist
1.730USD
-0.130-6.99%
Close 05/15, 16:00（ET）Quotes delayed by 15 min
228.42MMarket Cap
LossP/E TTM
More Details of Inhibikase Therapeutics Inc Company
Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing Abelson Tyrosine Kinase inhibitor therapeutics for cardiopulmonary disease. The Company’s multi-therapeutic pipeline includes IKT-001, a prodrug of imatinib mesylate, for pulmonary arterial hypertension (PAH).
Inhibikase Therapeutics Inc Info
Ticker SymbolIKT
Company nameInhibikase Therapeutics Inc
IPO dateDec 23, 2020
CEOIwicki (Mark T)
Number of employees15
Security typeOrdinary Share
Fiscal year-endDec 23
Address1000 N. West Street, Suite 1200
CityWILMINGTON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code19801
Phone13022953800
Websitehttps://www.inhibikase.com/
Ticker SymbolIKT
IPO dateDec 23, 2020
CEOIwicki (Mark T)
Company Executives of Inhibikase Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Christopher H. (Chris) Cabell, M.D.
Dr. Christopher H. (Chris) Cabell, M.D.
President, Head - Research and Development
President, Head - Research and Development
676.56K
--
Mr. Vincent E. (Vince) Aurentz
Mr. Vincent E. (Vince) Aurentz
Independent Director
Independent Director
510.60K
--
Mr. Amit D. Munshi
Mr. Amit D. Munshi
Independent Chairman of the Board
Independent Chairman of the Board
403.18K
--
Mr. Arvind Kush
Mr. Arvind Kush
Independent Director
Independent Director
145.00K
--
Dr. Roy Freeman, M.D.
Dr. Roy Freeman, M.D.
Independent Director
Independent Director
--
--
Mr. Dennis N. Berman
Mr. Dennis N. Berman
Independent Director
Independent Director
--
--
Mr. Roberto Bellini
Mr. Roberto Bellini
Independent Director
Independent Director
--
-100.00%
Mr. David Canner, Ph.D.
Mr. David Canner, Ph.D.
Independent Director
Independent Director
--
--
Mr. Mike Moyer
Mr. Mike Moyer
Managing Director of LifeSci Advisors
Managing Director of LifeSci Advisors
--
--
Mr. Mark T. Iwicki
Mr. Mark T. Iwicki
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Christopher H. (Chris) Cabell, M.D.
Dr. Christopher H. (Chris) Cabell, M.D.
President, Head - Research and Development
President, Head - Research and Development
676.56K
--
Mr. Vincent E. (Vince) Aurentz
Mr. Vincent E. (Vince) Aurentz
Independent Director
Independent Director
510.60K
--
Mr. Amit D. Munshi
Mr. Amit D. Munshi
Independent Chairman of the Board
Independent Chairman of the Board
403.18K
--
Mr. Arvind Kush
Mr. Arvind Kush
Independent Director
Independent Director
145.00K
--
Dr. Roy Freeman, M.D.
Dr. Roy Freeman, M.D.
Independent Director
Independent Director
--
--
Mr. Dennis N. Berman
Mr. Dennis N. Berman
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, May 10
Updated: Sun, May 10
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Sands Capital Ventures LLC
9.86%
Soleus Capital Management, L.P.
8.24%
Fairmount Funds Management LLC
6.53%
Adar1 Capital Management LLC
6.11%
Trails Edge Capital Partners LP
4.68%
Other
64.58%
Shareholders
Shareholders
Proportion
Sands Capital Ventures LLC
9.86%
Soleus Capital Management, L.P.
8.24%
Fairmount Funds Management LLC
6.53%
Adar1 Capital Management LLC
6.11%
Trails Edge Capital Partners LP
4.68%
Other
64.58%
Shareholder Types
Shareholders
Proportion
Hedge Fund
43.67%
Investment Advisor
20.91%
Investment Advisor/Hedge Fund
9.78%
Corporation
4.42%
Private Equity
4.11%
Individual Investor
2.00%
Research Firm
0.40%
Bank and Trust
0.07%
Pension Fund
0.04%
Other
14.61%
Institutional Shareholding
Updated: Wed, Apr 1
Updated: Wed, Apr 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2026Q1
152
103.21M
78.17%
+43.85M
2025Q4
122
64.55M
53.39%
+6.52M
2025Q3
110
54.77M
73.50%
+878.44K
2025Q2
87
62.36M
83.88%
+6.72M
2025Q1
82
60.21M
81.40%
+7.53M
2024Q4
61
58.78M
83.36%
+15.59M
2024Q3
38
1.99M
24.34%
-203.16K
2024Q2
42
2.13M
28.26%
+379.22K
2024Q1
47
1.51M
21.65%
-625.47K
2023Q4
49
1.53M
25.68%
-638.36K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Sands Capital Ventures LLC
13.02M
9.86%
--
--
Dec 31, 2025
Soleus Capital Management, L.P.
10.88M
8.24%
+4.55M
+71.94%
Dec 31, 2025
Fairmount Funds Management LLC
8.63M
6.53%
+2.50M
+40.82%
Dec 31, 2025
Adar1 Capital Management LLC
8.06M
6.11%
+2.82M
+53.67%
Dec 31, 2025
Trails Edge Capital Partners LP
6.18M
4.68%
+6.18M
--
Dec 31, 2025
Blackstone Alternative Asset Management, L.P.
5.94M
4.5%
+3.30M
+125.08%
Dec 31, 2025
Invus Public Equities Advisors, LLC
5.85M
4.43%
+5.85M
--
Dec 31, 2025
SP IKT Holdings LLC
5.84M
4.42%
--
--
Mar 16, 2026
Perceptive Advisors LLC
5.42M
4.11%
--
--
Dec 31, 2025
Commodore Capital LP
5.40M
4.09%
--
--
Dec 31, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0.02%
iShares Russell 2000 Value ETF
0.01%
ProShares Hedge Replication ETF
0%
iShares Russell 2000 ETF
0%
iShares Russell 2000 Growth ETF
0%
Global X Russell 2000 ETF
0%
Proshares Ultra Russell 2000
0%
ProShares UltraPro Russell2000
0%
iShares Micro-Cap ETF
Proportion0.02%
iShares Russell 2000 Value ETF
Proportion0.01%
ProShares Hedge Replication ETF
Proportion0%
iShares Russell 2000 ETF
Proportion0%
iShares Russell 2000 Growth ETF
Proportion0%
Global X Russell 2000 ETF
Proportion0%
Proshares Ultra Russell 2000
Proportion0%
ProShares UltraPro Russell2000
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
Jun 29, 2023
Merger
6→1
Jun 29, 2023
Merger
6→1
Jun 29, 2023
Merger
6→1
Jun 29, 2023
Merger
6→1
Date
Ex-dividend Date
Type
Ratio
Jun 29, 2023
Merger
6→1
Jun 29, 2023
Merger
6→1
Jun 29, 2023
Merger
6→1
Jun 29, 2023
Merger
6→1
